Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

SLN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Silence Therapeutics plcNASDAQ: SLN

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows 200.1% year over year

Q1 FY2026 weighted avg shares (diluted) of 47.23M shares rose 200.1% year over year. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +63.9% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
47.23M+0.0% QoQ
Last fiscal yearDec 2025
47.23M+206.4% YoY
LTMMar 2026
31.49M— YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+200.1%——
1 year+206.4%——
3-year CAGR+63.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
47.23M USD
Year-over-year change
—

Weighted Avg Shares (Diluted) vs competitors

How SLN compares with its peers on the latest reported figures

  • SLN's LTM Mar 2026 weighted avg shares (diluted) of 31.49M shares is the 7th highest of the 9 companies compared; the peer median is 107.17M shares.
  • Over three fiscal years its annual growth of +63.9% compares with a peer median of +9.9%.
SLN Competitors Peer median
Weighted Avg Shares (Diluted) for SLN and competitors
Company Period LTM YoY 3-year CAGR
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +19.3%+28.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M -0.2%+4.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026142.03M +6.4%+9.9%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026108.39M +6.9%+6.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026105.94M +21.0%+13.7%
BNTCBenitec Biopharma Inc.LTM Mar 202643.27M +112.6%+166.1%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+0.4%
RNAAtrium Therapeutics, Inc.FY202517.11M ——
ADRXADARx Pharmaceuticals, Inc.—— ——
Peer median (excluding SLN) 107.17M+6.9%+9.9%

Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Revenue12.42M17.65M25.38M43.26M559K
Cost of Revenue7.46M10.97M10.32M11.81M215K
Gross Profit4.96M6.68M15.06M31.45M344K
Gross Margin39.9%37.8%59.3%72.7%61.5%
Research & Development30.77M35.5M44.03M67.88M67.75M
Selling, General & Admin20.01M20.94M20.64M26.88M22.34M
Operating Expenses50.77M56.44M64.66M94.77M90.1M
Depreciation & Amortization427K485.86K498K593K555K
EBITDA(45.42M)(39.94M)(49.78M)(48.99M)(88.05M)
EBITDA Margin-365.9%-226.2%-196.2%-113.2%-15750.6%
Operating Income(45.81M)(49.76M)(49.6M)(63.32M)(89.75M)
Operating Margin-369.0%-281.9%-195.5%-146.4%-16056.0%
Interest Income10K226K1.45M4.47M3.48M
Interest Expense8K47K34K00
Other Income / Expenses(42K)9.29M(706K)18.86M1.15M
Income Before Tax(45.86M)(40.47M)(50.31M)(44.46M)(88.6M)
Pre-Tax Margin-369.4%-229.3%-198.3%-102.8%-15849.9%
Income Tax Expense(6.45M)560.85K(7.04M)845K11K
Net Income(39.41M)(41.03M)(43.27M)(45.31M)(88.61M)
Net Margin-317.4%-232.4%-170.5%-104.7%-15851.9%
EPS (Basic)(1.35)(3.78)(3.48)(2.37)(1.89)
EPS (Diluted)(1.35)(3.78)(3.48)(2.37)(1.89)
Weighted Avg Shares29.65M10.73M12.36M15.42M47.23M
Weighted Avg Shares (Diluted)29.65M10.73M12.36M15.42M47.23M

Silence Therapeutics plc

NASDAQ:SLN

Intrinsic Alpha fair value

Locked

Current Price

$19.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.